Sarmen Sarkissian, MD In this phase 2 study published in JCO, researchers added everolimus to fulvestrant in female patients with stage IV breast CA, ER+ Her2 negative, that had progressed on an aromatase inhibitor. There was a 20% improvement in the clinical benefit rate as well as an improvement of 5 months in the median progression free survival. http://ascopubs.org/doi/abs/10.1200/JCO.2017.76.9331 [...]
